» Articles » PMID: 33606065

Development and Validation of a PD-L1/PD-1/CD8 Axis-based Classifier to Predict Cancer Survival of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy

Overview
Date 2021 Feb 19
PMID 33606065
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The expression status of programmed cell death-ligand 1/programmed cell death 1 (PD-L1/PD-1) and the infiltration of CD8 T cells in tumor tissues are considered to be related to immunotherapy efficacy and patient prognosis. The purpose of this study is to clarify the prognostic value of the PD-L1/PD-1/CD8 axis, and to develop and validate a comprehensive scoring system based on multiple immune variables to predict cancer survival of upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). The immunohistochemical method was used to detect the expression of PD-L1, PD-1, and CD8 in cancer tissues of UTUC patients after RNU. Then, an immunoscore was constructed using the least absolute shrinkage and selection operator (LASSO) Cox regression model in the training cohort (n = 120), and it was verified in the validation cohort (n = 54). We found that infiltration of PD-L1 immune cells (ICs), stromal PD-1 tumor-infiltrating lymphocytes (TILs), and intratumoral CD8 TILs was associated with poor overall survival (OS). The immunoscore based on the three immune variables further divided the patients into low- and high-risk groups, and there was a significant difference in the survival rate. A nomogram was constructed by combining tumor-node-metastasis (TNM) stage and immunoscore, and the area under the curve of the receiver-operating characteristic (ROC) (0.78) for predicting 5-year mortality was better than that of the TNM stage (0.70) and immunoscore (0.76). Our results show that the PD-L1/PD-1/CD8 axis-based classifier have potential clinical application to predict cancer survival of UTUC patients after RNU.

Citing Articles

Distribution and clinicopathological characteristics of G-CSF expression in tumor cells and stromal cells in upper tract urothelial carcinoma.

Kobayashi G, Sekino Y, Nakahara H, Kobatake K, Goto K, Hayashi T J Cancer Res Clin Oncol. 2024; 151(1):18.

PMID: 39739128 PMC: 11685250. DOI: 10.1007/s00432-024-06045-1.


SUSD2 cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy.

Su R, Sun X, Luo Y, Gu L, Wang F, Dong A Gastric Cancer. 2024; 28(2):245-263.

PMID: 39656339 DOI: 10.1007/s10120-024-01572-9.


A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery.

Pallauf M, Konig F, DAndrea D, Laukhtina E, Mostafaei H, Sari Motlagh R Front Oncol. 2022; 12:907975.

PMID: 35847838 PMC: 9283688. DOI: 10.3389/fonc.2022.907975.


Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.

Liao Y, He D, Wen F Immunogenetics. 2021; 73(5):369-380.

PMID: 34302518 DOI: 10.1007/s00251-021-01223-8.

References
1.
Wen T, Wang Z, Li Y, Li Z, Che X, Fan Y . A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer. Cancer Immunol Res. 2017; 5(7):524-534. DOI: 10.1158/2326-6066.CIR-16-0381. View

2.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

3.
Cha J, Chan L, Li C, Hsu J, Hung M . Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019; 76(3):359-370. PMC: 6981282. DOI: 10.1016/j.molcel.2019.09.030. View

4.
Ye S, Li X, Zhao K, Feng T . High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: A cohort study. Medicine (Baltimore). 2017; 96(15):e6472. PMC: 5403074. DOI: 10.1097/MD.0000000000006472. View

5.
Zhou L, Li Y, Gao W, Huangfu H, Wen S, Zhang C . Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 2019; 145(7):1761-1772. DOI: 10.1007/s00432-019-02936-w. View